Skip to Main Content

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Conditions

Prostate

Phase III

What is the purpose of this trial?

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

  • Ages
    18 years and older
  • Gender
    Male only
  • Trial with
    Memorial Sloan-Kettering Cancer Center
  • Start Date
    11/26/2019
  • End Date
    06/29/2022

For more information about this study, contact:

Matthew Piscatelli

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/02/2019
  • Study HIC
    #2000023885